A laboratory name still in the clinic
Phenobarbital is the everyday English name of a long-acting barbiturate: a white crystalline drug used as a sedative, a hypnotic, and, above all, an anticonvulsant in epilepsy. Chemists write the same substance as 5-ethyl-5-phenylbarbituric acid, which is barbital with one of its two ethyl groups replaced by a phenyl ring. British medical English long used phenobarbitone for the identical compound. The international nonproprietary name is phenobarbital.
The word is a pharmaceutical coinage, not an inherited household term. It never developed a broad figurative life. What it names has stayed remarkably stable even as its place in therapy has narrowed.
Assembled in English from two ready pieces
The medicine is older than the English generic. In 1911 Heinrich Hörlein, then heading pharmaceutical research at Bayer, made the compound by grafting a phenyl group onto the barbital skeleton. Bayer marketed it in 1912 as Luminal. That year it was tried as a sleeping drug, and Alfred Hauptmann, a psychiatrist in Freiburg, noticed that epileptic inpatients given it for sedation had fewer seizures, including during the day. The observation turned a new hypnotic into the first clearly effective drug for epilepsy.
The English common noun arrives later. Merriam-Webster and Etymonline both date the first known use to 1919; Dictionary.com gives a slightly wider window of 1915–20. The gap is not mysterious. Trade names and German chemical descriptions circulated first. The English word is not a borrowing from Old French and not a native Old English inheritance. It is a transparent scientific compound: the combining form pheno- plus the older drug name barbital.
That morphology is the whole story of how the form entered the language. Once chemists had barbital, they could prefix pheno- to mark the phenyl analogue, just as they later built pentobarbital, amobarbital, and related names on the same stem.
Pheno-: benzene by way of lamp gas
In chemical English, pheno- (phen- before a vowel) marks a compound related to benzene or carrying a phenyl group. That is the sense that matters here. The phenyl ring is exactly the structural difference between phenobarbital and barbital.
The prefix is not home-grown. It comes through nineteenth-century French laboratory naming. In 1836 Auguste Laurent proposed phène as a name for benzene because the substance had been taken from coal tar, a by-product of making illuminating gas. He drew the stem from Greek phainein, to bring to light or cause to appear. The same Greek verb feeds English phenomenon, phantom, and related words, but inside phenobarbital the Greek arrives only at second hand, via the name for benzene derivatives. There is a separate scientific pheno- meaning appearing or shining, as in phenotype. That is a sibling formation, not the piece inside this drug name.
The first half of the word, then, is a compressed chemical instruction: this barbiturate carries a phenyl group.
Barbital, urea, and an unsettled Barbara
Barbital is the first barbiturate sold as a medicine: diethylbarbituric acid, brought into the clinic in 1903–1904 under the brand Veronal. The English name is built from barbituric plus the chemical ending -al. Evidence for barbital as an English noun clusters in the 1910s. Patients and doctors had already met the drug under its proprietary label.
Barbituric looks back to German Barbitursäure, coined by Adolf von Baeyer in the early 1860s for malonylurea, the parent ring of the whole class. The second half is urea: the compound was obtained in connection with uric acid. The first half is not settled. Later stories attach it to a woman named Barbara, to St. Barbara’s day and a celebration with artillery officers, to Latin barbata in the name of a bearded lichen, or even to the look of the crystals. None of these can be proved from a naming note by Baeyer himself, and careful accounts treat the Barbara element as tradition rather than documented fact. What is solid is the German chemical name, then French barbiturique, then English barbituric, barbiturate, and barbital.
Cognate names keep the same skeleton. German uses Phenobarbital; Spanish and Portuguese have fenobarbital; Finnish has fenobarbitaali. Inside English the family includes pentobarbital, secobarbital, and methylphenobarbital. The British -one forms — barbitone, phenobarbitone, amylobarbitone — are not different substances. They are the older British Approved Names, now largely replaced by the international -al names.
Veronal, the brand for barbital, is a separate naming episode. One oft-repeated account says Josef von Mering chose it after a telegram from Emil Fischer reached him when his train stopped at Verona. That story belongs to the predecessor drug, not to phenobarbital, but it shows how freely chemists of the period mixed systematic stems with private labels. Luminal is the parallel brand for the phenyl compound; phenobarbital is the systematic English generic that grew up beside it.
A narrow sense, a shifting job
The lexical meaning has stayed tight: this is a pharmaceutical noun. What changed is medical use. Luminal entered the clinic as a longer-acting hypnotic than barbital and was soon called, in hospital slang of the time, the king of the barbiturates. Hauptmann’s 1912 paper made anticonvulsant the sense that would keep the word in print. World War I slowed its spread outside Germany; phenobarbitone was not marketed in Britain until 1923. Newer anticonvulsants later took much of its routine work, and benzodiazepines displaced barbiturates as everyday sedatives. The name did not need a new definition. It still names the same phenyl-substituted barbiturate, now used in a smaller set of epileptic and emergency settings.
What the pieces still show
If you strip the word, the laboratory decision that created the drug is still readable. Pheno- records the phenyl ring; barbital records the barbituric core and, behind that, urea. The origin of the word phenobarbital is therefore unusually transparent for a long scientific compound, except at one point: the barb- in barbituric acid, where the stories multiply and the evidence does not.